Literature DB >> 26168215

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Douglas Marvel, Dmitry I Gabrilovich.   

Abstract

Our understanding of the role of myeloid-derived suppressor cells (MDSCs) in cancer is becoming increasingly complex. In addition to their eponymous role in suppressing immune responses, they directly support tumor growth, differentiation, and metastasis in a number of ways that are only now beginning to be appreciated. It is because of this increasingly complex role that these cells may become an important factor in the treatment of human cancer. In this Review, we discuss the most pertinent and controversial issues of MDSC biology and their role in promoting cancer progression and highlight how these cells may be used in the clinic, both as prognostic factors and as therapeutic targets.

Entities:  

Mesh:

Year:  2015        PMID: 26168215      PMCID: PMC4588239          DOI: 10.1172/JCI80005

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  124 in total

1.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

2.  The terminology issue for myeloid-derived suppressor cells.

Authors:  Dmitry I Gabrilovich; Vincenzo Bronte; Shu-Hsia Chen; Mario P Colombo; Augusto Ochoa; Suzanne Ostrand-Rosenberg; Hans Schreiber
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

3.  Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.

Authors:  Inbal Mishalian; Rachel Bayuh; Liran Levy; Lida Zolotarov; Janna Michaeli; Zvi Gregorio Fridlender
Journal:  Cancer Immunol Immunother       Date:  2013-10-04       Impact factor: 6.968

4.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

5.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

6.  Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

Authors:  Hequan Li; Yanmei Han; Qiuli Guo; Minggang Zhang; Xuetao Cao
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

7.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

8.  Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8⁺ T cell priming.

Authors:  Navin R Mahadevan; Veronika Anufreichik; Jeffrey J Rodvold; Kevin T Chiu; Homero Sepulveda; Maurizio Zanetti
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

9.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.

Authors:  Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

10.  Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Authors:  Ahmad A Tarhini; Howard Edington; Lisa H Butterfield; Yan Lin; Yongli Shuai; Hussein Tawbi; Cindy Sander; Yan Yin; Matthew Holtzman; Jonas Johnson; Uma N M Rao; John M Kirkwood
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more
  413 in total

1.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Authors:  Jesse M Zaretsky; Angel Garcia-Diaz; Daniel S Shin; Helena Escuin-Ordinas; Willy Hugo; Siwen Hu-Lieskovan; Davis Y Torrejon; Gabriel Abril-Rodriguez; Salemiz Sandoval; Lucas Barthly; Justin Saco; Blanca Homet Moreno; Riccardo Mezzadra; Bartosz Chmielowski; Kathleen Ruchalski; I Peter Shintaku; Phillip J Sanchez; Cristina Puig-Saus; Grace Cherry; Elizabeth Seja; Xiangju Kong; Jia Pang; Beata Berent-Maoz; Begoña Comin-Anduix; Thomas G Graeber; Paul C Tumeh; Ton N M Schumacher; Roger S Lo; Antoni Ribas
Journal:  N Engl J Med       Date:  2016-07-13       Impact factor: 91.245

Review 2.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

3.  Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.

Authors:  Flavia Fontana; Raquél Bartolo; Hélder A Santos
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.

Authors:  Xiaojing Yue; Anjana Rao
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

5.  Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC.

Authors:  Maria Ozerova; Yulia Nefedova
Journal:  Leuk Lymphoma       Date:  2019-01-02

Review 6.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

7.  Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase.

Authors:  Irina Lerman; Maria de la Luz Garcia-Hernandez; Javier Rangel-Moreno; Luis Chiriboga; Chunliu Pan; Kent L Nastiuk; John J Krolewski; Aritro Sen; Stephen R Hammes
Journal:  Mol Cancer Res       Date:  2017-05-16       Impact factor: 5.852

8.  Melanoma induced immunosuppression is mediated by hematopoietic dysregulation.

Authors:  Neha Kamran; Youping Li; Maria Sierra; Mahmoud S Alghamri; Padma Kadiyala; Henry D Appelman; Marta Edwards; Pedro R Lowenstein; Maria G Castro
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

Review 9.  Considerations for successful cancer immunotherapy in aged hosts.

Authors:  V Hurez; Á S Padrón; R S Svatek; T J Curiel
Journal:  Clin Exp Immunol       Date:  2016-11-07       Impact factor: 4.330

Review 10.  Plasticity of myeloid-derived suppressor cells in cancer.

Authors:  Evgenii Tcyganov; Jerome Mastio; Eric Chen; Dmitry I Gabrilovich
Journal:  Curr Opin Immunol       Date:  2018-03-14       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.